STOCK TITAN

Form 144 Notice: Ionis Insider Sale of 51,800 Shares via Stifel

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ionis Pharmaceuticals Form 144 notice: A proposed sale of 51,800 shares of common stock is reported to be executed through Stifel Nicolaus & Company, Inc. on 09/03/2025 with an aggregate market value of $3,152,698.00. The filing lists total shares outstanding of 159,391,229. Acquisition details for the shares to be sold are disclosed: 46,800 were acquired by option exercise on 01/03/2022, 7,537 were restricted stock units dated 01/15/2017, and 6,373 were restricted stock units dated 01/15/2016. The filing also reports sales by Frank Bennett in the past three months: 10,000 shares on 08/18/2025 for $439,776.00, and two sales on 09/02/2025 of 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00). The filer signs a standard representation that no material nonpublic information is known. Other issuer contact and relationship fields are not populated in the provided content.

Positive

  • Proposed sale disclosed with specific trade date (09/03/2025), broker (Stifel) and aggregate market value ($3,152,698.00).
  • Acquisition history provided for the shares to be sold with dates and transaction types (option exercise and RSUs).
  • Prior sales listed for the past three months with amounts and gross proceeds (totaling 15,000 shares).

Negative

  • Issuer and relationship fields are not populated in the provided content, limiting context about the seller's role.
  • Filing does not state whether the seller is an officer, director, or large shareholder in the provided excerpt.

Insights

TL;DR: Routine insider sale filing disclosing 51,800 shares for $3.15M, with prior small sales by Frank Bennett.

The Form 144 is procedural: it notifies the SEC of a proposed sale of 51,800 Ionis common shares through Stifel on 09/03/2025 valued at $3,152,698. The filing details the acquisition method and dates for the lots to be sold, indicating option exercise and restricted stock unit origins. Reported prior sales by Frank Bennett total 15,000 shares across August and September 2025 with disclosed gross proceeds. The filing does not include issuer relationship or additional context about the seller's role, limiting inference about insider status or intent.

TL;DR: Disclosure appears compliant but lacks populated issuer relationship and contact fields, leaving some contextual gaps.

The submitted Form 144 contains the essential trading specifics required for Rule 144 notices: class, broker, amounts, acquisition dates, and past three-month sales. However, several issuer information fields (issuer contact, relationship to issuer) are blank in the provided content, which reduces transparency about the seller's capacity. The filing includes the statutory attestation regarding absence of material nonpublic information, consistent with rule requirements.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Ionis (IONS) Form 144 report?

The filing reports a proposed sale of 51,800 Ionis common shares through Stifel on 09/03/2025 with aggregate market value $3,152,698.00.

How were the shares being sold acquired?

The shares listed were acquired via option exercise on 01/03/2022 (46,800 shares) and as restricted stock units on 01/15/2017 (7,537) and 01/15/2016 (6,373).

Did the filer sell any Ionis shares in the prior three months?

Yes. The filing discloses Frank Bennett sold 10,000 shares on 08/18/2025 for $439,776.00, and on 09/02/2025 sold 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00).

Who is the broker handling the proposed sale?

The broker named in the Form 144 is Stifel Nicolaus & Company, Inc.

Are there any undisclosed issuer details in the filing?

Yes. The provided content does not populate issuer contact, SEC file number, or the seller's relationship to the issuer.
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

12.79B
160.75M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD